<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393690</url>
  </required_header>
  <id_info>
    <org_study_id>RU241306I</org_study_id>
    <secondary_id>NCI-2015-00277</secondary_id>
    <secondary_id>14-008494</secondary_id>
    <secondary_id>RU241306I</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT02393690</nct_id>
  </id_info>
  <brief_title>Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer</brief_title>
  <official_title>Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Academic and Community Cancer Research United</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well iodine I-131 works with or without selumetinib in&#xD;
      treating patients with thyroid cancer that has returned (recurrent) or has spread from where&#xD;
      it started to other places in the body (metastatic). Many thyroid cancers absorb iodine. Due&#xD;
      to this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer&#xD;
      as part of standard practice. It is thought that the more thyroid tumors are able to absorb&#xD;
      radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors&#xD;
      to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still&#xD;
      absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or&#xD;
      without selumetinib in treating thyroid cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the response rate at 6 months following treatment with 131I (iodine I-131) in&#xD;
      combination with placebo or selumetinib for radioactive iodine-avid (RAIA) recurrent and/or&#xD;
      metastatic thyroid cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the best overall response following treatment with 131I in combination with&#xD;
      placebo or selumetinib for RAIA recurrent and/or metastatic thyroid cancer.&#xD;
&#xD;
      II. To compare the progression-free survival of patients with RAIA recurrent and/or&#xD;
      metastatic thyroid cancer treated with 131I in combination with placebo or selumetinib.&#xD;
&#xD;
      III. To compare serum thyroglobulin changes for patients with RAIA recurrent and/or&#xD;
      metastatic thyroid cancer treated with 131I in combination with placebo or selumetinib.&#xD;
&#xD;
      IV. To evaluate the safety and tolerability of 131I in combination with placebo or&#xD;
      selumetinib for patients with RAI-avid recurrent and/or metastatic thyroid cancer.&#xD;
&#xD;
      CORRELATIVE OBJECTIVE:&#xD;
&#xD;
      I. To explore the genomic and transcriptomic landscape of RAIA tumors for signatures that&#xD;
      correlate to therapeutic benefit achieved with 131I in combination with placebo or&#xD;
      selumetinib.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive selumetinib orally (PO) twice daily (BID) starting on week 1, day 1&#xD;
      and continuing through 2 days after iodine I-131 therapy has been administered. Approximately&#xD;
      3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.&#xD;
&#xD;
      ARM II: Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2&#xD;
      days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning&#xD;
      treatment with placebo, patients receive iodine I-131 PO.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1 and 3 months, every 3&#xD;
      months for 12 months, and then every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2015</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Actual">July 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response at 6 Months</measure>
    <time_frame>At 6 months</time_frame>
    <description>A patient will be classified as a responder if they have a partial or complete response at the 6-month time point when compared to the baseline, pre-study radiologic scan(s). A Complete Response (CR) is defined as the disappearance of all target lesions and thyroglobulin measured to be less than 0.2 ng/ml. A Partial Response (PR) is defined as at least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the long or short axis of all the target lymph nodes (depending on which axis is being used for assessments) at current evaluation) taking as reference the baseline sum of dimensions (BSD). &gt;&#xD;
&gt; A patient will be classified as a responder if they have a partial or complete response at the 6-month time point. The proportion of patients with a response will be calculated and compared between the 2 Arms using a Fisher's Exact test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The best overall response will be compared between the two arms. This comparison will be done using a chi-square test. For a patient to be classified as a response, they need a partial or complete response that is confirmed at least 4 weeks later anytime during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Thyroglobulin Levels</measure>
    <time_frame>Baseline to up to 2 years</time_frame>
    <description>Changes in serum thyroglobulin levels will be compared between the 2 treatment arms using the Wilcoxon Rank-Sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Genomic and Transcriptomic Landscape of Radioactive Iodine-avid (RAIA) Tumors</measure>
    <time_frame>Baseline</time_frame>
    <description>Will explore the genomic and transcriptomic landscape of RAIA tumors for signatures that correlate to therapeutic benefit achieved in patients with RAI-avid recurrent and/or metastatic thyroid cancer treated with 131I in combination with placebo or selumetinib. Exploratory analysis will include correlating response to tumor genotypes. Descriptive statistics and graphical techniques will be used to summarize this data by treatment arm.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Metastatic Thyroid Gland Carcinoma</condition>
  <condition>Poorly Differentiated Thyroid Gland Carcinoma</condition>
  <condition>Recurrent Thyroid Gland Carcinoma</condition>
  <condition>Stage IV Thyroid Gland Follicular Carcinoma AJCC v7</condition>
  <condition>Stage IV Thyroid Gland Papillary Carcinoma AJCC v7</condition>
  <condition>Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7</condition>
  <condition>Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7</condition>
  <condition>Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7</condition>
  <condition>Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7</condition>
  <condition>Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7</condition>
  <condition>Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm I (selumetinib, iodine I-131)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo, iodine I-131)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Iodine I-131</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (selumetinib, iodine I-131)</arm_group_label>
    <arm_group_label>Arm II (placebo, iodine I-131)</arm_group_label>
    <other_name>131-Iodine</other_name>
    <other_name>Bound Iodide I-131</other_name>
    <other_name>I 131</other_name>
    <other_name>I-131</other_name>
    <other_name>Iodide I-131</other_name>
    <other_name>Iodide, I-131</other_name>
    <other_name>Iodine 131</other_name>
    <other_name>Iodotope</other_name>
    <other_name>Iodotrope</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo, iodine I-131)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (selumetinib, iodine I-131)</arm_group_label>
    <other_name>ARRY-142886</other_name>
    <other_name>AZD6244</other_name>
    <other_name>MEK Inhibitor AZD6244</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of recurrent and/or metastatic thyroid cancer&#xD;
&#xD;
          -  Histological or cytological confirmation of thyroid carcinoma of follicular origin&#xD;
             (including papillary, follicular, or poorly differentiated subtypes and their&#xD;
             respective variants); NOTE: medullary and anaplastic thyroid cancers are excluded;&#xD;
             Hurthle cell carcinomas are excluded (defined as having an invasive tumor composed of&#xD;
             &gt; 75% oncocytic [Hurthle] cells lacking the nuclear features of papillary carcinoma,&#xD;
             tumor necrosis, and marked mitotic activity); patients with oncocytic (Hurthle cell)&#xD;
             variants of papillary thyroid carcinoma (defined as a tumor composed of a majority of&#xD;
             oncocytic [Hurthle] cells having the nuclear features of papillary carcinoma) are&#xD;
             eligible to participate&#xD;
&#xD;
          -  RAI-avid lesion on a radioiodine scan (a diagnostic, post-therapy, or post-ablation&#xD;
             scans) performed =&lt; 24 months prior to registration, which suggests that therapy with&#xD;
             131I is justifiable in the judgment of the investigator&#xD;
&#xD;
          -  Clinically or radiographically evident structural disease; patients with measurable&#xD;
             disease and those with only non-measurable (&quot;non-target&quot;) structural disease&#xD;
             (according to modified Response Evaluation Criteria in Solid Tumors [RECIST] version&#xD;
             [v] 1.1 criteria) are eligible;&#xD;
&#xD;
        NOTE 1: Modification of the RECIST v1.1 measurable disease criteria includes a change in&#xD;
        the definition of what is considered a measurable malignant lymph node; a malignant lymph&#xD;
        node is considered measurable if any of the following apply:&#xD;
&#xD;
          -  It is noted to be RAI-avid on radioactive iodine imaging (diagnostic or post-therapy&#xD;
             whole body scans acceptable) and it measures &gt;= 1 cm in the long axis,&#xD;
&#xD;
          -  It is pathologically proven to be involved with thyroid cancer (by cytology or&#xD;
             pathology) and it measures &gt;= 1 cm in the long axis, or&#xD;
&#xD;
          -  Its short axis is &gt;= 1.5 cm when assessed by computed tomography (CT) scan NOTE 2:&#xD;
             Patients only with biochemical evidence of disease without structural evidence of&#xD;
             cancer are not eligible for this study&#xD;
&#xD;
               -  For patients with non-measurable, structural disease the following must apply:&#xD;
&#xD;
          -  Undetectable thyroglobulin antibody AND&#xD;
&#xD;
          -  A serum thyroglobulin of 10 ng/ml or greater in the context of suppressed&#xD;
             thyroid-stimulating hormone (TSH) (TSH =&lt; 0.4 mcU/ml) =&lt; 28 days prior to study&#xD;
             registration; use of any thyroglobulin assay is allowed, though all serum&#xD;
             thyroglobulin measurements for study purposes must be conducted with the same&#xD;
             thyroglobulin assay&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2&#xD;
&#xD;
               -  Able to swallow and retain orally-administered medication with no clinically&#xD;
                  significant gastrointestinal abnormalities that may alter absorption&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3 (obtained =&lt; 28 days prior to&#xD;
                  randomization)&#xD;
&#xD;
               -  Platelet count &gt;= 100,000/mm^3 (obtained =&lt; 28 days prior to randomization)&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dL (obtained =&lt; 28 days prior to randomization)&#xD;
&#xD;
               -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) (obtained =&lt; 28 days prior&#xD;
                  to randomization)&#xD;
&#xD;
               -  Aspartate transaminase (AST) =&lt; 2.5 x ULN (or =&lt; 5 x ULN in presence of liver&#xD;
                  metastases) (obtained =&lt; 28 days prior to randomization)&#xD;
&#xD;
               -  Creatinine =&lt; 1.5 mg/dL OR calculated creatinine clearance of &gt;= 50 ml/min by&#xD;
                  either the Cockcroft-Gault formula or 24-hours urine collection analysis&#xD;
                  (obtained =&lt; 28 days prior to randomization)&#xD;
&#xD;
               -  Negative pregnancy test performed =&lt; 7 days prior to registration for women of&#xD;
                  childbearing potential only&#xD;
&#xD;
               -  Provide informed written consent&#xD;
&#xD;
               -  Willing to return to enrolling institution for follow-up (during the Active&#xD;
                  Monitoring Phase of the study)&#xD;
&#xD;
          -  Note: during the Active Monitoring Phase of a study (i.e., active treatment and&#xD;
             observation), participants must be willing to return to the consenting institution for&#xD;
             follow-up&#xD;
&#xD;
               -  Willing to provide mandatory archival tumor tissue (block or minimum of 30&#xD;
                  unstained slides from a primary or recurrent/metastatic thyroid cancer) for&#xD;
                  correlative research purposes; NOTE: patients with less archival tumor tissue&#xD;
                  available may still be eligible for the study after discussion with Academic and&#xD;
                  Community Cancer Research United (ACCRU); receipt of archival tumor tissue is not&#xD;
                  required for study registration and initiation of therapy&#xD;
&#xD;
               -  Willing to provide mandatory blood samples for correlative research purposes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  131I therapy =&lt; 6 months prior to registration; Note: 131I administered solely for&#xD;
             diagnostic purposes is not considered 131I therapy&#xD;
&#xD;
          -  External beam radiation therapy =&lt; 28 days prior to registration; note: previous&#xD;
             treatment with radiation is allowed if the investigator judges it will not compromise&#xD;
             patient safety on the study&#xD;
&#xD;
          -  Having been treated with a total cumulative (lifetime) 131I therapeutic activity &gt; 800&#xD;
             mCi (excluding 131I activity administered for diagnostic scans)&#xD;
&#xD;
          -  Treatment with chemotherapy or targeted therapy (e.g. tyrosine kinase inhibitor) =&lt; 28&#xD;
             days prior to registration&#xD;
&#xD;
          -  Prior exposure to mitogen-activated protein kinase kinase (MEK), RAS, or RAF&#xD;
             inhibitors (note: previous exposure to sorafenib is allowed) OR history of&#xD;
             hypersensitivity to selumetinib, thyrotropin alpha (Thyrogen), or any excipient agents&#xD;
&#xD;
          -  Unresolved toxicity &gt; Common Terminology Criteria for Adverse Events (CTCAE) grade 2&#xD;
             from previous anti-cancer therapy, except for alopecia&#xD;
&#xD;
          -  Cardiac conditions as follows:&#xD;
&#xD;
               -  Uncontrolled hypertension (blood pressure [BP] &gt;=150/95 mmHg despite medical&#xD;
                  therapy)&#xD;
&#xD;
               -  Left ventricular ejection fraction &lt; 55% measured by echocardiography&#xD;
&#xD;
               -  Atrial fibrillation with a ventricular rate &gt; 100 beats per minute (bpm) on&#xD;
                  electrocardiogram (ECG) at rest&#xD;
&#xD;
               -  Symptomatic heart failure (New York Heart Association [NYHA] grade II-IV)&#xD;
&#xD;
               -  Prior or current cardiomyopathy&#xD;
&#xD;
               -  Severe valvular heart disease&#xD;
&#xD;
               -  Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical&#xD;
                  therapy)&#xD;
&#xD;
               -  Acute coronary syndrome =&lt; 6 months prior to registration&#xD;
&#xD;
          -  Ophthalmological conditions as follows:&#xD;
&#xD;
               -  Intra-ocular pressure &gt; 21 mmHg, or uncontrolled glaucoma (irrespective of&#xD;
                  intra-ocular pressure)&#xD;
&#xD;
               -  Current or past history of central serous retinopathy or retinal vein occlusion&#xD;
&#xD;
          -  Symptomatic or untreated leptomeningeal disease, brain metastasis, or spinal cord&#xD;
             compression&#xD;
&#xD;
          -  Unable to follow a low iodine diet or requiring medication with high content in iodide&#xD;
             (e.g., amiodarone)&#xD;
&#xD;
          -  Received iodinated intravenous contrast within =&lt; 2 months of registration; avoidance&#xD;
             of iodinated oral contrast is also preferred but not strictly required for study&#xD;
             enrollment; NOTE: those who have had iodinated intravenous contrast within this time&#xD;
             frame may still be eligible if a urinary iodine analysis reveals that excess iodine&#xD;
             has been cleared (defined as urinary iodine documented to be &lt; 300 mcg/day by either a&#xD;
             spot urinary iodine or 24-hour urinary iodine measurement)&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens&#xD;
&#xD;
          -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)&#xD;
             positive and currently receiving antiretroviral therapy; NOTE: patients known to be&#xD;
             HIV positive, but without clinical evidence of an immunocompromised state, are&#xD;
             eligible for this trial&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, hepatitis B infection, hepatitis C infection, symptomatic congestive heart&#xD;
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Receiving any other investigational agent which would be considered as a treatment for&#xD;
             the primary neoplasm. (NOTE: Performance of investigational 124I PET/CT scans is&#xD;
             allowed prior to and during conduct of this study)&#xD;
&#xD;
          -  Other active malignancy =&lt; 2 years prior to registration that will interfere with&#xD;
             conduct of this trial; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of&#xD;
             the cervix; NOTE: if there is a history of prior malignancy, patients must not be&#xD;
             receiving other specific treatment (chemotherapy, hormonal therapy, radiation) for&#xD;
             their cancer&#xD;
&#xD;
          -  Not willing to discontinue use of supplemental vitamin E&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan L Ho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic and Community Cancer Research United</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <results_first_submitted>July 13, 2021</results_first_submitted>
  <results_first_submitted_qc>July 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Adenocarcinoma, Follicular</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02393690/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Selumetinib, Iodine I-131)</title>
          <description>Patients receive 75 mg selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Placebo, Iodine I-131)</title>
          <description>Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients registered to protocol treatment are included in this analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Selumetinib, Iodine I-131)</title>
          <description>Patients receive 75 mg selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Placebo, Iodine I-131)</title>
          <description>Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="20" upper_limit="78"/>
                    <measurement group_id="B2" value="61" lower_limit="24" upper_limit="83"/>
                    <measurement group_id="B3" value="62" lower_limit="20" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response at 6 Months</title>
        <description>A patient will be classified as a responder if they have a partial or complete response at the 6-month time point when compared to the baseline, pre-study radiologic scan(s). A Complete Response (CR) is defined as the disappearance of all target lesions and thyroglobulin measured to be less than 0.2 ng/ml. A Partial Response (PR) is defined as at least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the long or short axis of all the target lymph nodes (depending on which axis is being used for assessments) at current evaluation) taking as reference the baseline sum of dimensions (BSD). &gt;&#xD;
&gt; A patient will be classified as a responder if they have a partial or complete response at the 6-month time point. The proportion of patients with a response will be calculated and compared between the 2 Arms using a Fisher's Exact test.</description>
        <time_frame>At 6 months</time_frame>
        <population>All patients that began protocol treatment and were evaluable for this endpoint are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Selumetinib, Iodine I-131)</title>
            <description>Patients receive 75 mg selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo, Iodine I-131)</title>
            <description>Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.</description>
          </group>
        </group_list>
        <measure>
          <title>Response at 6 Months</title>
          <description>A patient will be classified as a responder if they have a partial or complete response at the 6-month time point when compared to the baseline, pre-study radiologic scan(s). A Complete Response (CR) is defined as the disappearance of all target lesions and thyroglobulin measured to be less than 0.2 ng/ml. A Partial Response (PR) is defined as at least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the long or short axis of all the target lymph nodes (depending on which axis is being used for assessments) at current evaluation) taking as reference the baseline sum of dimensions (BSD). &gt;&#xD;
&gt; A patient will be classified as a responder if they have a partial or complete response at the 6-month time point. The proportion of patients with a response will be calculated and compared between the 2 Arms using a Fisher's Exact test.</description>
          <population>All patients that began protocol treatment and were evaluable for this endpoint are included.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".138" lower_limit="0.038" upper_limit="0.317"/>
                    <measurement group_id="O2" value="0.065" lower_limit="0.008" upper_limit="0.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response</title>
        <description>The best overall response will be compared between the two arms. This comparison will be done using a chi-square test. For a patient to be classified as a response, they need a partial or complete response that is confirmed at least 4 weeks later anytime during the study.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Thyroglobulin Levels</title>
        <description>Changes in serum thyroglobulin levels will be compared between the 2 treatment arms using the Wilcoxon Rank-Sum test.</description>
        <time_frame>Baseline to up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Genomic and Transcriptomic Landscape of Radioactive Iodine-avid (RAIA) Tumors</title>
        <description>Will explore the genomic and transcriptomic landscape of RAIA tumors for signatures that correlate to therapeutic benefit achieved in patients with RAI-avid recurrent and/or metastatic thyroid cancer treated with 131I in combination with placebo or selumetinib. Exploratory analysis will include correlating response to tumor genotypes. Descriptive statistics and graphical techniques will be used to summarize this data by treatment arm.</description>
        <time_frame>Baseline</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at the end of each 28 day cycle. The max number of cycles taken was 8.</time_frame>
      <desc>Adverse events were collected at the end of each 28 day cycle. The max number of cycles taken was 8.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Selumetinib, Iodine I-131)</title>
          <description>Patients receive 75 mg selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Placebo, Iodine I-131)</title>
          <description>Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Oth spec</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="28"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="50" subjects_affected="20" subjects_at_risk="28"/>
                <counts group_id="E2" events="41" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gen disord and admin site conds-Oth spec</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Oth spec</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="16" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="21" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Scalp pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="44" subjects_affected="16" subjects_at_risk="28"/>
                <counts group_id="E2" events="34" subjects_affected="15" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Ho, M.D.</name_or_title>
      <organization>Academic and Community Cancer Research United (ACCRU)</organization>
      <phone>212-639-7202</phone>
      <email>hoa@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

